Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ideagen Plc LSE:IDEA London Ordinary Share GB00B0CM0C50 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.50p +0.37% 137.00p 32,956 08:19:33
Bid Price Offer Price High Price Low Price Open Price
135.00p 139.00p 137.00p 136.50p 136.50p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 36.12 1.40 0.77 177.9 301.1

Ideagen (IDEA) Latest News

More Ideagen News
Ideagen Takeover Rumours

Ideagen (IDEA) Share Charts

1 Year Ideagen Chart

1 Year Ideagen Chart

1 Month Ideagen Chart

1 Month Ideagen Chart

Intraday Ideagen Chart

Intraday Ideagen Chart

Ideagen (IDEA) Discussions and Chat

Ideagen (IDEA) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
09:59:26138.502,8403,933.40O
09:48:51137.368,10011,126.16O
08:39:08136.0012,01616,341.76O
07:19:03136.455,0006,822.50O
07:16:52137.505,0006,875.00O
View all Ideagen trades in real-time

Ideagen (IDEA) Top Chat Posts

DateSubject
24/5/2019
09:20
Ideagen Daily Update: Ideagen Plc is listed in the Software & Computer Services sector of the London Stock Exchange with ticker IDEA. The last closing price for Ideagen was 136.50p.
Ideagen Plc has a 4 week average price of 128p and a 12 week average price of 128p.
The 1 year high share price is 174p while the 1 year low share price is currently 119p.
There are currently 219,784,656 shares in issue and the average daily traded volume is 448,227 shares. The market capitalisation of Ideagen Plc is £301,104,978.72.
14/5/2019
09:38
leavers: Solid results, very nice. One point of caution is that adjusted EBITDA is +30% but they had a big placing in Sept so after that dilution adjusted EPS might only show a +20% increase to around 5.2p, giving them a current PER of 25-26 area. Recurring revenues are jumping but on that multiple and with organic growth of just 8%, I don't think that gives the shares a ton of short-term upside potential. If you look a year forward and guess adjusted EPS of +25% to 6.5 that could maybe justify a 160p ish share price but the stock will need some further news on acquisitions to get there. So my view is solid results, a touch light on organic growth and as always watch the valuation. The shares have been pretty weak for the last month and are flat over 6 months which suggests to me they are up with events. I was hoping for a little more on the revenues/ebitda growth side and given I am very heavy in the shares I will definitely trim my holding at the 150 area if we see that again soon.
28/4/2019
08:06
glasshalfull: I’m currently writing a brief synopsis on each of my holdings...& IDEA remains one of the cornerstones of it. Not sure if the earnings table can be transferred over so here’s the link HTTPS://twitter.com/glasshalfull1/status/1122073947959439362?s=12 SPRING PORTFOLIO 2019 WRITE-UPS (1) IDEA (IDEAGEN PLC) - Mr Dependable * Share Price 147p * M/Cap £323m * Enterprise Value £324m * Shares in Issue 219.8m * Stock Rank 41 (Quality 67 / Value 4) Similar to my previous updates, Ideagen is now a 14x bagger for me in my 9-years invested & unsurprisingly remains a cornerstone of my portfolio. They provide Integrate Risk Management (IRM) software & services to organisations operating in highly regulated industries. We are talking industry sectors across the globe from aviation and healthcare to banking & finance. It has a global presence & a customer base that includes many of the world’s blue-chip companies. Over 4,700 organisations use Ideagen's products including 7 of the top 10 UK accounting firms, ALL of the top aerospace & defence companies AND 75% of the world's leading pharmaceutical companies. Importantly they have a fantastic customer retention rate which has been circa. 95% for as long as I can remember. In terms of the numbers, they released positive H1 results in Jan 2019 & highlighted continued strong growth with recurring revs rising to 67% which provides increased visibility on earnings. SaaS revenues grew at +80% & now comprise 26% of overall revenues. This is a v important metric to watch as it de-risks forecasts & reliance of one-off software licence revenues. Ideagen has delivered 8 years of unbroken double-digit EPS growth. Worth pointing out that the growth in EPS is forecast at only +15% in FY19 simply due to a £20m placing in Sept 2018 (142p) & the subsequent timing of acquisitions. Yr end April Revenue Adj PBT Adj EPS 2010 £1.0m £0.2m 0.6p 2011 £2.3m £0.5m (+150%) 0.9p (+50%) 2012 £4.0m £1.0m (+100%) 1.26p (+40%) 2013 £6.5m £1.9m (+90%) 1.55p (+33%) 2014 £9.0m £2.6m (+37%) 1.7p (+12%) 2015 £14.4m £3.6m (+38%) 2.1p (+27%) 2016 £21.9m £5.7m (+58%) 2.7p (+26%) 2017 £27.1m £6.9m (+22%) 3.2p (+19%) 2018 £36.1m £9.7m (+40%) 4.2p (+32%) 2019e £46.5m £12.1m (+25%) 4.8p (+15%) I met the team early in 2019 at their H1 FY19 presentation & came away v impressed. In his first year as CEO, Ben Dorks has done an excellent job, with a superb grip on operational performance. This builds on the excellent development of the company under David Hornsby & I believe they are in very capable hands. By FY22 IDEA are targeting £100m revenue at 30% EBITDA margin with 74% of revenue recurring. finnCap have a 180p price target which is +22% from the current price. While this may appear a touch rich at a first glance, I’d suggest that it’s warranted as they’ve delivered in spades in the last 9-years; operate in a risk management market growing at +13% per annum; have fantastic client retention; strong recurring revenues & an offering that has increased enormously in breadth & depth via 16 x acquisitions that have delivered an enviable product set across multiple industries throughout the globe. Yes, Ideagen is my number 1, my GOALIE in the portfolio team & a company I believe my Mr DEPENDABLE. I’m sure it will remain a core holding for some time to come 😁 Kind regards, GHF
05/10/2018
21:17
garbetklb: Hi Rivaldo Sorry - my post wasn't clear. RNS 23/03/17 announcing the 2017 LTIP awarded Spenceley / Dorks / Kent 1,200,000 options each at 1p. At today's share price of circa 150p, that's circa £5.4m - yes, I accept that it wasn't worth that at the time of the award, but it's a lot of money - excessive, in my view. I see your interpretation re your 3rd point; not sure I agree. Looking at the (presumably summary) of the LTIP conditions, in order for the full award to be made the share price has to exceed 136p for 30 consecutive business days - from a quick glance, I suspect that has been achieved just now. What happens if the price subsequently drops isn't spelt out in the 23/03/17 RNS. IF it says that the share price has to exceed 136p for THE 30 days prior to exercising the option, I reckon today's announcement could be in the "bird in the hand" category for 50% of the award. Regardless, I'm not keen on such levels of remuneration, especially relative to profits. Others may be more relaxed, given growth etc. That's why we don't all buy the same shares! Good luck to all holders.
05/10/2018
12:26
rivaldo: As regards Garbetklb's post, firstly a total of 1.8m shares have been issued, i.e at the current price around £2.7m (no idea where his £5.2m comes from). Secondly, only one director fully sold their resulting shares. The other two have only sold 50% of their additional shares - enough only to cover costs and income tax payable (which would of course be taxed at the higher rate of 40%). Thirdly, the early exercise of the LTIP shares - without a full resultant sale - is a GOOD sign. This is usually done because the people exercising wish to minimise their tax liability by exercising early rather than waiting, since they presumably believe that by waiting the share price will rise sufficiently such that they would have a much higher income tax liability.
21/9/2018
11:25
speedsgh: 'Kiss of IC' ;-) Share price taking a well-earned breather. It is nearly the weekend after all.
13/9/2018
23:01
breeze3337: A 7% dilution. Will the share price reflect this on placement of the new shares?
13/9/2018
11:53
rivaldo: Great news - a quick £20m placing at 142p to fund a variety of acquisitions which are already identified and should be completed within weeks. Only recently we'd have been over the moon at raising money at 142p, so no complaints here, and the discount to the current share price is really pretty tiny. And note the para on current trading: Https://www.investegate.co.uk/ideagen-plc--idea-/rns/proposed-placing-to-raise--20-million/201809131130017085A/ "Current Trading and Outlook Trading remains robust and in line with management expectations. The Company is seeing strong demand for its products from new customers and the Board are pleased to see further growth in its recurring revenues."
13/9/2018
09:17
rivaldo: Shares Magazine today features IDEA as one of their Great Idea updates, and conclude: "A now largely proven quality business, investors should stick with the stock for further share price upside." Interestingly, they also say: "remember, management have their own 200p internal share price target, and we would not bet against such optimism."
18/5/2018
06:54
rivaldo: That's an interesting article in Shares Magazine, disclosing the internal 200p share price target and noting that current forecasts could be beaten "by a wide margin". Other useful snippets: GRC "is a $7bn-a-year GRC market yet it remains highly fragmented. Ideagen, which has been around since 1993, wants to act as an industry consolidator as well as driving consistent organic growth." "It aims to double revenue and profit every three years and has met or beaten those targets in the past. For example, in 2015 it reported revenue of £14.4m and £3.6m pre-tax profit. The year to 30 April 2018 is expected to show £36.1m of sales and £9.7m of pre-tax profit. Throughout this growth the company has remained highly cash generative and paid modest dividends. The US is now its number one growth market, as it is the world’s single biggest place for GRC spending. That means accelerating acquisitions growth, such as April’s $8.7m purchase of Medforce, a healthcare compliance business." "The net of regulation red tape and compliance accountability is getting ever tighter around industries and organisations across the world. The next big one is EUwide General Data Protection Regulation (GDPR) which comes into force on 25 May and is the latest in a long list of rules designed to keep us better protected. All this puts UK software supplier Ideagen (IDEA:AIM) in a sweet spot thanks to its wide range of off-the-shelf specialised tools. The Midlands-based company concentrates on what it calls the governance, risk and compliance (GRC) space, providing information management solutions to highly regulated industries. Think healthcare, aviation, banking/finance, complex manufacturing, defence and energy."
28/1/2018
11:44
rivaldo: The article itself says the Mail first tipped IDEA when the share price was 33p. So it's more than tripled since then, which is hardly "featuring a share after its bolted". Much share tipstering is indeed helping out mates, jumping on bandwagons etc. But not all. The Mail is due at least a little credit in this instance :o)) "Clever ideas like this have helped Ideagen to more than triple in size since Midas first recommended the firm in 2014. Then, shares were 33p, turnover was £9 million and profit was £2.6 million."
Ideagen share price data is direct from the London Stock Exchange
Your Recent History
LSE
IDEA
Ideagen
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190524 11:56:27